In silico study on the heterogeneity of the dose distribution and radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy

被引：0
|
作者：
Birindelli, G. [1 ]
Drobnjakovic, M. [1 ]
Morath, V. [2 ]
Steiger, K. [3 ]
D'Alessandria, C. [2 ]
Gourni, E. [1 ]
Afshar-Oromieh, A. [1 ]
Weber, W. [2 ]
Rominger, A. [1 ]
Eiber, M. [2 ]
Shi, K. [1 ]
机构：
[1] Univ Bern, Inselspital, Bern, Switzerland
[2] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany
[3] Tech Univ Munich, Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0049
引用
收藏
页码：S24 / S25
页数：2
相关论文
共 27 条
  • [21] Concurrent use of 90Y, 177Lu and 225Ac-labelled PSMA-binding radiopharmaceuticals can lead to improved treatment efficacy
    Denis-Bacelar, A. M.
    Fenwick, A. J.
    Ferreira, K. M.
    Wevrett, J. L.
    Robinson, A. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S271 - S272
  • [22] Therapeutic efficacy and clinical outcome of 177Lu-PSMA-617/225Ac-PSMA-617 radioligand therapy in metastatic castration resistant prostate cancer (mCRPC) - single institutional experience from India
    Kalra, Kriti
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [23] 225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)
    Rosar, Florian
    Khreish, Fadi
    Nagel, Lea Sophie
    Blickle, Arne
    Burgard, Caroline
    Petto, Sven
    Bastian, Moritz B.
    Speicher, Tilman
    Bartholomae, Mark
    Maus, Stephan
    Schaefer-Schuler, Andrea
    Ezziddin, Samer
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (04) : e202 - e206
  • [24] 225Ac-PSMA / 177Lu-PSMA Tandem Therapy for Metastatic Castration-Resistant Prostate Cancer (a)over-cap(sic)" A Prospective Phase 3 Randomized Study from Azerbaijan
    Novruzov, Fuad
    Mehdi, Elnur
    Shukurov, Razim
    Dadashov, Zamil
    Guliyev, Fuad
    Musayev, Teymur
    Paez, Diana
    Aliyev, Altay
    Giammarile, Francesco
    Aliyev, Jamil
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [25] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
    Nauseef, Jones T.
    Sun, Michael Philip
    Thomas, Charlene
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Fernandez, Escarleth
    Davidson, Zachary
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Castellanos, Sandra Huicochea
    Gregos, Peter
    Osborne, Joseph
    Ballman, Karla V.
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and betaradioligand 177Lu-PSMA I&T
    Tagawa, Scott T.
    Sun, Michael Philip
    Nauseef, Jones T.
    Thomas, Charlene
    Castellanos, Sandra Huicochea
    Thomas, Joseph Earl
    Davidson, Zachary
    Stangl-Kremser, Judith
    Bissassar, Mahelia
    Palmer, Jessica
    Tan, Angela
    Patel, Amie
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
123